Key Takeaways
- Health Canada finalized its Software as a Medical Device (SaMD) guidance in January 2026, providing a clear regulatory pathway for prescription digital therapeutics.
- Three prescription digital therapeutics have received Health Canada authorization to date, covering insomnia, substance use disorder, and chronic low back pain.
- The global DTx market is projected to reach US$56 billion by 2030; Canada’s domestic share is estimated at $1.8-2.4 billion.
- Canadian companies Mindset Health, Freespira Canada, and Nuvation Health are advancing DTx programs through the new regulatory framework.
Prescription software that treats clinical conditions digital therapeutics, or DTx has been one of health technology’s most discussed and least regulated categories for the past decade. The products have been real: Pear Therapeutics’ reSET for substance use disorder, Somryst for chronic insomnia, and a growing cohort of digital cognitive behavioural therapy platforms with clinical evidence behind them. What has been missing, in Canada as in most markets, is a clear regulatory framework that distinguishes clinically validated digital therapeutics from the wellness app ecosystem and creates a pathway to reimbursement. Health Canada’s finalized SaMD guidance, published in January 2026, provides that framework and is beginning to unlock a new asset class for Canadian investors.
What Health Canada’s SaMD Framework Actually Says
Health Canada’s Software as a Medical Device guidance classifies software-based medical devices on a risk-tiered basis. Software intended to drive clinical decisions or treat clinical conditions falls into the higher-risk classifications (Class II through Class IV), while software providing general wellness or health information falls outside the medical device framework entirely. The key regulatory determination is the software’s intended use: if the software claims to diagnose, treat, prevent, or cure a medical condition, it requires market authorization as a medical device.
For prescription digital therapeutics software prescribed by a physician to treat a specific clinical condition the regulatory pathway is Class III, requiring a premarket submission demonstrating safety and effectiveness through clinical evidence. This is analogous to the regulatory standard for a pharmaceutical drug or a Class III medical device, reflecting Health Canada’s view that software capable of treating clinical conditions carries comparable risk to physical medical products.
| Digital Therapeutic Category | Regulatory Class (HC) | Clinical Evidence Standard | Reimbursement Status (Canada) | Example Products |
|---|---|---|---|---|
| Chronic insomnia (CBT-I) | Class III | RCT, non-inferiority to active control | Limited (2 provincial pilots) | Somryst, Sleepio |
| Substance use disorder | Class III | RCT vs. standard of care | Not covered (private pay) | reSET (Pear/Sandoz) |
| Chronic low back pain | Class III | RCT, validated pain/function outcomes | Not covered | Kaia Health |
| ADHD (digital phenotyping + therapy) | Class II–III | Superiority to sham digital control | Not covered | EndeavorRx (US only) |
| Diabetes management | Class II | Real-world evidence + clinical outcomes | Partial (CGM-linked) | Onduo, One Drop |
| Mental health (anxiety/depression CBT) | Class II–III | RCT, validated psychiatric scales | Not covered (piloting) | Freespira Canada |
The Three Authorized Canadian DTx Products
As of mid-2026, three prescription digital therapeutics have received Health Canada market authorization under the new SaMD framework. Somryst (for chronic insomnia, licensed by Mindset Health for Canadian distribution) was the first, receiving Class III authorization in March 2026. A substance use disorder DTx, developed by Sandoz Canada in partnership with the original Pear Therapeutics IP library, received authorization in May 2026. The third a digital CBT-based chronic low back pain program received authorization in June 2026 and is targeted at the primary care and physiotherapy prescription market.
None of the three are currently reimbursed by provincial health plans as standalone prescription products, though Ontario and British Columbia have launched pilot programs that reimburse Somryst in mental health clinic settings. The reimbursement gap is the primary commercial challenge for prescription DTx in Canada without coverage, adoption depends on patient willingness to pay out-of-pocket, which limits penetration to higher-income populations and undermines the equity case for these technologies.
Canadian Companies in the DTx Space
Mindset Health, the Australian-originated company with significant Canadian operations in Toronto, has built a DTx library across insomnia, anxiety, irritable bowel syndrome, and menopause all with RCT evidence and several with Health Canada authorization pending. Freespira Canada is adapting the US-cleared Freespira breathing-based anxiety treatment platform for Canadian regulatory submission. Nuvation Health, a Toronto-based startup, is developing an oncology-specific DTx that addresses chemotherapy-induced symptoms through validated digital CBT protocols.
The Bottom Line
Health Canada’s SaMD framework has removed the regulatory uncertainty that has held back prescription digital therapeutic adoption in Canada for years. The framework creates a legitimate asset class Health Canada-authorized clinical software that physicians can prescribe with the same confidence they prescribe medications. The remaining barriers are reimbursement and physician awareness; both are addressable over a 24-to-36-month horizon as clinical evidence accumulates and provincial HTAs evaluate the cost-effectiveness case for DTx reimbursement. For investors willing to play a long game, the prescription DTx sector in Canada represents one of the few health technology categories where the regulatory foundation is now in place and the commercial and reimbursement infrastructure is being built in real time.